Search

Displaying results 6241 - 6250 of 9865 in total
  1. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  2. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, … Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells.

  3. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  4. Drug

    Teverelix

    go.drugbank.com/drugs/DB05624
    Investigational

    A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

    International brands: Teverelix LA
  5. Drug

    Sodium stibogluconate

    go.drugbank.com/drugs/DB05630
    ApprovedInvestigational

    Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials.

    Synonyms: Stibogluconate de sodium
  6. Drug

    KP-1461

    go.drugbank.com/drugs/DB05644
    Investigational

    Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases. … KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue.

  7. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.

  8. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.

  9. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

  10. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.